Biodel Inc. reported positive effects of VIAject™ insulin on microvascular function in patients with Type 2 diabetes which were superior to results seen with regular human insulin and insulin lispro.   

Professor Thomas Forst, MD, Institute for Clinical Research and Development (IKFE), Mainz, Germany, and principal investigator of the study, presented the findings today at the Eighth Annual Diabetes Technology Meeting in Bethesda, MD.

In the randomized cross-over pilot study, 14 patients were treated before mealtime on three days with three different insulin therapies: regular human insulin (RHI), insulin lispro (90 % of the RHI dose) and insulin VIAject™ (90 % of the RHI dose). 

The purpose of the study was to measure the effects of insulin on vascular function, as measured by biomarkers for oxidative stress and atherosclerosis, and clinical measures of tissue blood flow and tissue oxygenation. VIAject™ was found to be the most effective of the three insulins in improving microvasular blood flow and endothelial function and reducing postprandial oxidative stress.

Dr. Forst stated: “Our results were most favorable when patients received VIAject™, and were independent of glycemic control. This demonstrates the importance of the timing of insulin release (pharmacokinetic profile) in the protection of the vasculature against atherosclerosis. These results are encouraging and warrant further clinical study to investigate potential beneficial effects of ultra-rapid-acting insulin on microvascular and cardiovascular function.”